Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review
Cells · 28.08.2023 · 12 (17) · 2159
DOI: 10.3390/cells12172159 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.08.2023. Verfasst von Mariusz Kaczmarek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Poznan University of Medical Sciences, 61-866 Poznań, Poland. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 259-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In recent years, there has been a surge of interest in tumor microenvironment-associated cancer vaccine therapies. These innovative treatments aim to activate and enhance the body’s natural immune response against cancer cells by utilizing specific antigens present in the tumor microenvironment. The goal is to achieve a complete clinical response, where all measurable cancer cells are either eliminated or greatly reduced in size. With their potential to revolutionize cancer treatment, these therapies represent a promising avenue for researchers and clinicians alike. Despite over 100 years of research, the success of therapeutic cancer vaccines has been variable, particularly in advanced cancer patients, with various limitations, including the heterogeneity of the tumor microenvironment, the presence of immunosuppressive cells, and the potential for tumor escape mechanisms. Additionally, the effectiveness of these therapies may be limited by the variability of the patient’s immune system response and the difficulty in identifying appropriate antigens for each patient. Despite these challenges, tumor microenvironment-targeted vaccine cancer therapies have shown promising results in preclinical and clinical studies and have the potential to become a valuable addition to current cancer treatment and “curative” options. While chemotherapeutic and monoclonal antibody treatments remain popular, ongoing research is needed to optimize the design and delivery of these therapies and to identify biomarkers that can predict response and guide patient selection. This comprehensive review explores the mechanisms of cancer vaccines, various delivery methods, and the role of adjuvants in improving treatment outcomes. It also discusses the historical background of cancer vaccine research and examines the current state of major cancer vaccination immunotherapies. Furthermore, the limitations and effectiveness of each vaccine type are analyzed, providing insights into the future of cancer vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, Poznan University of Medical Sciences, 61-866 Poznań, Poland.
- Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Center, 61-866 Poznań, Poland.
- Scientific Society of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.
ORCID-Profile: Mariusz Kaczmarek, Andrzej Mackiewicz
Zitieren
APA
Kaczmarek, M., Poznańska, J., Fechner, F., Michalska, N., Paszkowska, S., Napierała, A., & Mackiewicz, A. (2023). Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review. Cells, 12(17), 2159. https://doi.org/10.3390/cells12172159
Vancouver
Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review. Cells. 2023;12(17):2159. doi:10.3390/cells12172159
BibTeX
@article{Kaczmarek2023,
author = {Kaczmarek, Mariusz and Poznańska, Justyna and Fechner, Filip and Michalska, Natasza and Paszkowska, Sara and Napierała, Adrianna and Mackiewicz, Andrzej},
title = {Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review},
journal = {Cells},
year = {2023},
volume = {12},
number = {17},
pages = {2159},
doi = {10.3390/cells12172159}
}
EUVIMED